Message From the Editor-in-Chief
The Circulation Journal Official Impact Factor and the Most Frequently Cited Papers in 2022
2023 Volume 87 Issue 9 Pages 1151-1154
Details
2023 Volume 87 Issue 9 Pages 1151-1154
Dear Colleagues,
On behalf of the Circulation Journal, I would like to report its official 2022 Impact Factor and the related information in detail as follows:
I would like to report that Circulation Journal has earned an official 2022 Impact Factor of 3.3 (2021: 3.350). The official ranking places Circulation Journal the 67th among the 142 journals in the Cardiac & Cardiovascular Systems category in 2022 JCR Science Edition (72nd among the 143 journals in 2021). I would like to ask readers to use Circulation Journal papers as reference papers in your future submission of manuscripts to any journals.
The following papers, published in 2020–2021, are the top 30 most frequently cited papers in 2022, thereby substantially contributing to the 2022 Impact Factor of the Journal. Numbers in the parenthesis denote the number of citations in 2022.
1. (54) Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J 2020; 84: 1348–1407.
2. (49) Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J 2020; 84: 831–865.
3. (41) Izumi C, Eishi K, Ashihara K, Arita T, Otsuji Y, Kunihara T, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease. Circ J 2020; 84: 2037–2119.
4. (37) Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 2020; 84: 1610–1671.
5. (27) Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, et al; JCS on behalf of the JCS/JHRS Joint Working Group. JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. Circ J 2021; 85: 1104–1244.
6. (20) Yamagishi M, Tamaki N, Akasaka T, Ikeda T, Ueshima K, Uemura S, et al; on behalf of the Japanese Circulation Society Working Group. JCS 2018 guideline on diagnosis of chronic coronary heart diseases. Circ J 2021; 85: 402–572.
7. (17) Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Sakata Y, et al; on behalf of the PARALLEL-HF Investigators. Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction: Results from the PARALLEL-HF study. Circ J 2021; 85: 584–594.
8. (16) Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al; on behalf of the JCS Joint Working Group. JCS 2017 guideline on management of vasculitis syndrome: Digest version. Circ J 2020; 84: 299–359.
(16) Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al; on behalf of the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. Circ J 2021; 85: 2252–2291.
10. (15) Chew NW, Sia CH, Wee HL, Benedict LJ, Rastogi S, Kojodjojo P, et al. Impact of the COVID-19 pandemic on door-to-balloon time for primary percutaneous coronary intervention: Results from the Singapore Western STEMI network. Circ J 2021; 85: 139–149.
(15) Deguchi H, Ikeda M, Ide T, Tadokoro T, Ikeda S, Okabe K, et al. Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice. Circ J 2020; 84: 1028–1033.
(15) Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J 2021; 85: 1590–1689.
13. (14) Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Lipoprotein(a) and cardiovascular diseases: Revisited. Circ J 2020; 84: 867–874.
14. (13) Hisatome I, Li P, Miake J, Taufiq F, Mahati E, Maharani N, et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease: Japanese guideline on the management of asymptomatic hyperuricemia. Circ J 2021; 85: 130–138.
15. (11) Ide T, Kaku H, Matsushima S, Tohyama T, Enzan N, Funakoshi K, et al; the JROADHF Investigators. Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF). Circ J 2021; 85: 1438–1450.
(11) Saito S, Yamazaki S, Takahashi A, Namiki A, Kawasaki T, Otsuji S, et al; for the Disrupt CAD IV Investigators. Intravascular lithotripsy for vessel preparation in severely calcified coronary arteries prior to stent placement: Primary outcomes from the Japanese disrupt CAD IV study. Circ J 2021; 85: 826–833.
17. (10) Noda T, Nishigaki K, Minatoguchi S. Safety and efficacy of human muse cell-based product for acute myocardial infarction in a first-in-human trial. Circ J 2020; 84: 1189–1192.
(10) Choi KH, Yang JH, Hong D, Park TK, Lee JM, Song YB, et al. Optimal timing of venoarterial-extracorporeal membrane oxygenation in acute myocardial infarction patients suffering from refractory cardiogenic shock. Circ J 2020; 84: 1502–1510.
(10) Ishii H, Amano T, Yamaji K, Kohsaka S, Yokoi H, Ikari Y. Implementation of percutaneous coronary intervention during the COVID-19 pandemic in Japan: Nationwide survey report of the Japanese association of cardiovascular intervention and therapeutics for cardiovascular disease. Circ J 2020; 84: 2185–2189.
(10) Tilz RR, Meyer-Saraei R, Eitel C, Fink T, Sciacca V, Lopez LD, et al. Novel cryoballoon ablation system for single shot pulmonary vein isolation: The prospective ICE-AGE-X study. Circ J 2021; 85: 1296–1304.
21. (9) Li T, Gu J, Yang O, Wang J, Wang Y, Kong J. Bone marrow mesenchymal stem cell-derived exosomal miRNA-29c decreases cardiac ischemia/reperfusion injury through inhibition of excessive autophagy via the PTEN/Akt/mTOR signaling pathway. Circ J 2020; 84: 1304–1311.
(9) Khalifa AKM, Kubo T, Ino Y, Terada K, Emori H, Higashioka D, et al. Optical coherence tomography comparison of percutaneous coronary intervention among plaque rupture, erosion, and calcified nodule in acute myocardial infarction. Circ J 2020; 84: 911–916.
(9) Matsumoto S, Kuroda S, Sano T, Kitai T, Yonetsu T, Kohsaka S, et al. Clinical and biomarker profiles and prognosis of elderly patients with Coronavirus Disease 2019 (COVID-19) with cardiovascular diseases and/or risk factors. Circ J 2021; 85: 921–928.
24. (8) Xie Y, You Q, Wu C, Cao S, Qu G, Yan X, et al. Impact of cardiovascular disease on clinical characteristics and outcomes of Coronavirus Disease 2019 (COVID-19). Circ J 2020; 84: 1277–1283.
(8) Gawalko M, Balsam P, Lodzinski P, Grabowski M, Krzowski B, Opolski G, et al. Cardiac arrhythmias in autoimmune diseases. Circ J 2020; 84: 685–694.
(8) Natsuaki M, Morimoto T, Shiomi H, Ehara N, Taniguchi R, Tamura T, et al; on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators. Application of the modified high bleeding risk criteria for Japanese patients in an all-corners registry of percutaneous coronary intervention: From the CREDO-Kyoto registry cohort-3. Circ J 2021; 85: 769–781.
(8) Sato T, Calderon RJC, Klas B, Pedrizzetti G, Banerjee A. Simultaneous volumetric and functional assessment of the right ventricle in hypoplastic left heart syndrome after fontan palliation, utilizing 3-dimensional speckle-tracking echocardiography. Circ J 2020; 84: 235–244.
(8) Murakami N, Kokubu N, Nagano N, Nishida J, Nishikawa R, Nakata J, et al. Prognostic impact of no-flow time on 30-day neurological outcomes in patients with out-of-hospital cardiac arrest who received extracorporeal cardiopulmonary resuscitation. Circ J 2020; 84: 1097–1104.
(8) Tada H, Okada H, Nohara A, Yamagishi M, Takamura M, Kawashiri M. Effect of cumulative exposure to low-density lipoprotein-cholesterol on cardiovascular events in patients with familial hypercholesterolemia. Circ J 2021; 85: 2073–2078.
(8) Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, et al. Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients: A randomized controlled trial. Circ J 2020; 84: 1807–1817.
The following papers are the top 41 most frequently cited papers among the 8,035 papers published in the Circulation Journal (2002–2022). Numbers in the parenthesis denote the number of citations.
1. (1341) Matsuzawa Y, Nakamura T, Takahashi M, Ryo M, Inoue S, Ikeda Y, et al. New criteria for ‘obesity disease’ in Japan. Circ J 2002; 66: 987–992. (Review)
2. (566) Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975–981.
3. (552) Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213–220. (Review)
4. (539) Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411–418. (Review)
5. (467) Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; on behalf of the J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF Study. Circ J 2012; 76: 2104–2111.
6. (432) Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818–826. (Review)
7. (399) Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010; 74: 2257–2262. (Review)
8. (346) Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J 2009; 73: 595–601. (Review)
9. (343) Inoue H, Atarashi H, Kamakura S, Koretsune Y, Kumagai K, Mitamura H, et al; JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997–2021.
10. (274) Ogawa H, Akasaka T, Hattori R, Inoue T, Kawashima S, Kawasuji M, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013): Digest version. Circ J 2014; 78: 2779–2801.
(274) Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007; 71: 536–539.
12. (269) Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928–933.
13. (264) Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79: 495–502. (Review)
14. (253) Ando J, Yamamoto K. Vascular mechanobiology: Endothelial cell responses to fluid shear stress. Circ J 2009; 73: 1983–1992. (Review)
15. (252) Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al; the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. Circ J 2019; 83: 2084–2184.
16. (238) Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al; for the JCARE-CARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893–1900.
17. (235) Ueyama T, Kasamatsu K, Hano T, Yamamoto K, Tsuruo Y, Nishio I. Emotional stress induces transient left ventricular hypocontraction in the rat via activation of cardiac adrenoceptors: A possible animal model of ‘Takotsubo’ cardiomyopathy. Circ J 2002; 66: 712–713.
18. (233) Tomiyama H, Yamashina A. Non-invasive vascular function tests: Their pathophysiological background and clinical application. Circ J 2010; 74: 24–33. (Review)
19. (225) Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012; 76: 485–488.
20. (220) Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006; 70: 1437–1442.
21. (219) Kawai S, Kitabatake A, Tomoike H; Takotsubo Cardiomyopathy Study Group. Guidelines for diagnosis of Takotsubo (ampulla) cardiomyopathy. Circ J 2007; 71: 990–992.
22. (216) Swift DL, Lavie CJ, Johannsen NM, Arena R, Earnest CP, O’Keefe JH, et al. Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J 2013; 77: 281–292. (Review)
23. (215) Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684–1692.
24. (205) Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008; 72: 598–604.
25. (201) Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008; 72: 489–491.
26. (199) Ogura R, Hiasa Y, Takahashi T, Yamaguchi K, Fujiwara K, Ohara Y, et al. Specific findings of the standard 12-lead ECG in patients with ‘Takotsubo’ cardiomyopathy: Comparison with the findings of acute anterior myocardial infarction. Circ J 2003; 67: 687–690.
(199) Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. Circ J 2011; 75: 1287–1296. (Review)
28. (197) Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597–607. (Review)
(197) Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815–822.
30. (195) Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N, et al. Normal range of left ventricular 2-dimensional strain: Japanese ultrasound speckle tracking of the left ventricle (JUSTICE) study. Circ J 2012; 76: 2623–2632.
31. (189) Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J 2019; 83: 1085–1196.
(189) Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 2013; 77: 1111–1122. (Review)
33. (188) Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, et al. Pulse wave velocity predicts cardiovascular mortality: Findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005; 69: 259–264.
34. (187) Ando M, Fukuda I, Ito M, Kobayashi T, Masuda M, Miyahara Y, et al; JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009): Digest version. Circ J 2011; 75: 1258–1281.
35. (185) Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013; 77: 705–711.
36. (184) Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: A pilot study. Circ J 2012; 76: 1750–1760.
37. (180) Ogawa H, Akasaka T, Hattori R, Kawashima S, Kawasuji M, Kimura K, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): Digest version. Circ J 2010; 74: 1745–1762.
38. (178) Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, Chen J, et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J 2013; 77: 1307–1314.
39. (177) Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia: Primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1087–1095.
40. (176) Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome: Randomized, double-blind, phase III PHILO study. Circ J 2015; 79: 2452–2460.
(176) Ehara M, Surmely JF, Kawai M, Katoh O, Matsubara T, Terashima M, et al. Diagnostic accuracy of 64-slice computed tomography for detecting angiographically significant coronary artery stenosis in an unselected consecutive patient population: Comparison with conventional invasive angiography. Circ J 2006; 70: 564–571.
The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.
